"In 180 day exclusivity period in anti-diabetic drug in US market, Glenmark recorded superlative performance with more than 100 percent growth. I believe that the stock holds promise to grow between 30 percent and 40 percent upside in next 12-18 months time", Deven Choksey of KRChoksey Investment Managers told CNBC-TV18.
first published: Feb 3, 2017 09:35 am
A collection of the most-viewed Moneycontrol videos.
This Tenant says Andheri West is better than SOBO | The tenant
Nifty Clocks Second Week Of Gains But Still Awaits New Peak;Midcaps Snap 7-Week Run|Closing Bell
Will Nifty Bulls March Towards Fresh Peak Despite Dismal Global Cues? | Opening Bell Live
Nifty Aims For Next 26,100 After Hitting 3-Week High |Opening Bell Live
